PathVision AI Intraoperative Pathology System Earns FDA Approval: 60-Second Diagnosis During Surgery
DiagnosTech's PathVision intraoperative pathology system received FDA approval, enabling surgeons to obtain AI-assisted pathology results within 60 seconds of extracting a tissue sample, helping determine resection margins in real time.
Pathology AI company DiagnosTech announced on April 30 that its PathVision intraoperative pathology system has received FDA approval. Traditional intraoperative pathology analysis takes 30 to 45 minutes — surgeons must wait on the operating table for frozen-section results while the patient remains under anesthesia.
PathVision compresses that timeline dramatically. A surgeon places the excised tissue sample on PathVision's high-resolution scanner, and the AI completes histological analysis in 60 seconds, delivering a benign-versus-malignant determination along with an assessment of surgical margin status.
In a clinical trial involving 3,000 cases, PathVision's diagnostic accuracy achieved 96% concordance with senior pathologists. The FDA classified PathVision as a Class II medical device. Pricing is set at $200 per test.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.